Efficacy of RTS, S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 …
AM Samuels, D Ansong, SK Kariuki, S Adjei… - The Lancet Infectious …, 2022 - thelancet.com
Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …
Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised …
S Rts - Lancet, 2015 - thelancet.com
Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …
18 months of follow-up have been published previously. Herein, we report the final results …
Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 …
RTS, S Clinical Trials Partnership (2014) - PLoS medicine, 2014 - journals.plos.org
Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …
Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
S Owusu-Agyei, D Ansong, K Asante… - PLoS …, 2009 - journals.plos.org
Background The target delivery channel of RTS, S candidate malaria vaccines in malaria-
endemic countries in Africa is the World Health Organisation Expanded Program on …
endemic countries in Africa is the World Health Organisation Expanded Program on …
Long-term incidence of severe malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 …
Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa
A Leach, J Vekemans, M Lievens, O Ofori-Anyinam… - Malaria journal, 2011 - Springer
Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …
are working in partnership to develop a malaria vaccine to protect infants and children living …
[HTML][HTML] First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children
RTS, S Clinical Trials Partnership - New England Journal of …, 2011 - Mass Medical Soc
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …
[HTML][HTML] Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
YG Mendoza, E Garric, A Leach, M Lievens… - Human vaccines & …, 2019 - Taylor & Francis
ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …
KP Asante, S Abdulla, S Agnandji, J Lyimo… - The Lancet infectious …, 2011 - thelancet.com
Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
JJ Aponte, P Aide, M Renom, I Mandomando, Q Bassat… - The Lancet, 2007 - thelancet.com
Background Malaria remains a leading global health problem that requires the improved
use of existing interventions and the accelerated development of new control methods. We …
use of existing interventions and the accelerated development of new control methods. We …